Citations (407)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (24)
Tingyu Liang, Yixuan Song, Lingui Gu, Yu Wang & Wenbin Ma. (2023) Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma. International Journal of General Medicine 16, pages 4121-4141.
Read now
Read now
Xiao Chen Ma, Xiao Lv & Ying Li. (2023) Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma. Expert Review of Hematology 0:0, pages 1-7.
Read now
Read now
Ming-Yao Sun, Wanyang Li & Wei Chen. (2023) Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G/Medhin, Gashaw Dessie Terefe, Fitalew Tadele Admasu, Wondwossen Wale Tesega & Endeshaw Chekol Abebe. (2022) Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Gülçin Telli Dizman, José María Aguado & Mario Fernández-Ruiz. (2022) Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Review of Anti-infective Therapy 20:11, pages 1455-1476.
Read now
Read now
Vahid Mansouri, Niloufar Yazdanpanah & Nima Rezaei. (2022) The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. International Reviews of Immunology 41:6, pages 649-668.
Read now
Read now
Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani & Fatemeh Rahbarizadeh. (2022) Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Critical Reviews in Biotechnology 42:7, pages 1079-1098.
Read now
Read now
Fateeha Furqan & Nirav N Shah. (2022) Bispecific CAR T-cells for B-cell Malignancies. Expert Opinion on Biological Therapy 22:8, pages 1005-1015.
Read now
Read now
Mina Hosseini, Zahra Habibi, Narges Hosseini, Sina Abdoli & Nima Rezaei. (2022) Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review. Expert Opinion on Biological Therapy 22:3, pages 349-366.
Read now
Read now
Othman Mohammad Saleh, Khaled Anwer Albakri, Yasmeen Jamal Alabdallat, Majd Hamdi Dajani & Walaa Bayoumie El Gazzar. (2022) The safety and efficacy of CAR-T cells in the treatment of prostate cancer: review. Biomarkers 27:1, pages 22-34.
Read now
Read now
Lidia Gatto, Enrico Franceschi, Vincenzo Di Nunno, Ilaria Maggio, Raffaele Lodi & Alba Ariela Brandes. (2021) Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. Expert Review of Anticancer Therapy 21:12, pages 1333-1353.
Read now
Read now
Natasha Bechman & John Maher. (2021) Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?. Expert Opinion on Biological Therapy 21:5, pages 627-637.
Read now
Read now
Varada Date & Sujit Nair. (2021) Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opinion on Biological Therapy 21:2, pages 145-160.
Read now
Read now
Tanvir F Kabir, Charles A Kunos, John L Villano & Aman Chauhan. (2020) Immunotherapy for Medulloblastoma: Current Perspectives. ImmunoTargets and Therapy 9, pages 57-77.
Read now
Read now
Mariya Lazarova, Winfried S. Wels & Alexander Steinle. (2020) Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system. Expert Opinion on Biological Therapy 20:12, pages 1491-1501.
Read now
Read now
Sidhant Jain & Sahil Kumar. (2020) Cancer immunotherapy: dawn of the death of cancer?. International Reviews of Immunology 39:5, pages 205-222.
Read now
Read now
Tarec Christoffer El-Galaly, Chan Yoon Cheah, Daniel Kristensen, Andrew Hutchison, Kevin Hay, Torbjörn Callréus & Diego Villa. (2020) Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. Acta Oncologica 59:7, pages 766-774.
Read now
Read now
Lingli Yan & Bainan Liu. (2019) Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. OncoTargets and Therapy 12, pages 193-204.
Read now
Read now
Hongbing Ma, Swaminathan Padmanabhan Iyer, Simrit Parmar & Yuping Gong. (2019) Adoptive cell therapy for acute myeloid leukemia. Leukemia & Lymphoma 60:6, pages 1370-1380.
Read now
Read now
Martyna Filipska, Carlos Pedraz-Valdunciel, Imane Chaib & Rafael Rosell. (2019) Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. Expert Opinion on Biological Therapy 19:5, pages 457-467.
Read now
Read now
Sofia Genta, Eleonora Ghisoni, Gaia Giannone, Gloria Mittica & Giorgio Valabrega. (2018) Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. Expert Opinion on Biological Therapy 18:4, pages 359-367.
Read now
Read now
Xuequn Xu, Jin Qiu & Yi Sun. (2017) The basics of CAR T design and challenges in immunotherapy of solid tumors — Ovarian cancer as a model. Human Vaccines & Immunotherapeutics 13:7, pages 1548-1555.
Read now
Read now
Niaz Muhammad, Qinwen Mao & Haibin Xia. (2017) CAR T-cells for cancer therapy. Biotechnology and Genetic Engineering Reviews 33:2, pages 190-226.
Read now
Read now
Yi Lin & Hideho Okada. (2016) Cellular immunotherapy for malignant gliomas. Expert Opinion on Biological Therapy 16:10, pages 1265-1275.
Read now
Read now
Articles from other publishers (383)
AIMAZ afrough, JinSeon Im, Nitin Jain & PARTOW kebriaei. 2024. Manual of Hematopoietic Cell Transplantation and Cellular Therapies. Manual of Hematopoietic Cell Transplantation and Cellular Therapies
233
245
.
Candida Vitale, Valentina Griggio, Francesca Perutelli & Marta Coscia. (2023) CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?. HemaSphere 7:12, pages e988.
Crossref
Crossref
Mikalai Katsin, Dmitri Dormeshkin, Alexander Meleshko, Alexandr Migas, Simon Dubovik & Natalya Konoplya. (2023) CAR-T Cell Therapy for Classical Hodgkin Lymphoma. HemaSphere 7:12, pages e971.
Crossref
Crossref
Yu Cao, Sergey K. Efetov, Mingze He, Yu Fu, Narasimha M. Beeraka, Jin Zhang, Xinliang Zhang, Namitha Bannimath & Kuo Chen. (2023) Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Archivum Immunologiae et Therapiae Experimentalis 71:1.
Crossref
Crossref
Courtney Chen, Audrey Jung, Annie Yang, Isabel Monroy, Zhifang Zhang, Shyambabu Chaurasiya, Supriya Deshpande, Saul Priceman, Yuman Fong, Anthony K. Park & Yanghee Woo. (2023) Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies. Cancers 15:23, pages 5661.
Crossref
Crossref
Kun Ma & Ping Hu. (2023) Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma. Cancers 15:23, pages 5652.
Crossref
Crossref
Hong Ma, Jeeban Das, Conor Prendergast, Dorine De Jong, Brian Braumuller, Jacienta Paily, Sophia Huang, Connie Liou, Anna Giarratana, Mahdie Hosseini, Randy Yeh & Kathleen Capaccione. (2023) Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer. Current Issues in Molecular Biology 45:11, pages 9019-9038.
Crossref
Crossref
Ye Li, Katayoun Rezvani & Hind Rafei. (2023) Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer. Immunological Reviews 320:1, pages 217-235.
Crossref
Crossref
Jie Tang & Xudong Zhao. (2023) Chimeric antigen receptor T cells march into T cell malignancies. Journal of Cancer Research and Clinical Oncology 149:14, pages 13459-13475.
Crossref
Crossref
Pei Liu, Josquin Foiret, Yinglin Situ, Nisi Zhang, Aris J. Kare, Bo Wu, Marina N. Raie, Katherine W. Ferrara & Lei S. Qi. (2023) Sonogenetic control of multiplexed genome regulation and base editing. Nature Communications 14:1.
Crossref
Crossref
Xuejin Gao, Jile Liu, Rui Sun, Jingkun Zhang, Xinping Cao, Yi Zhang & Mingfeng Zhao. (2023) Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies. Annals of Hematology.
Crossref
Crossref
Mohd Kausar, Sadaf Anwar, Hemat El‑Horany, Farida Khan, Neetu Tyagi, Mohammad Najm, - Sadaf, Alaa Eisa, Chandrajeet Dhara & Saumyatika Gantayat. (2023) Journey of CAR T‑cells: Emphasising the concepts and advancements in breast cancer (Review). International Journal of Oncology 63:6.
Crossref
Crossref
Shrikant Barot, Henis Patel, Anjali Yadav & Igor Ban. (2023) Recent advancement in targeted therapy and role of emerging technologies to treat cancer. Medical Oncology 40:11.
Crossref
Crossref
Richard Smith. (2023) Bringing cell therapy to tumors: considerations for optimal CAR binder design. Antibody Therapeutics 6:4, pages 225-239.
Crossref
Crossref
Mohammad Reza LahimchiFaezeh MaroufiAmirhosein Maali. (2023) Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy. Cellular Reprogramming 25:5, pages 195-211.
Crossref
Crossref
Lin Tang, Sheng Pan, Xuyong Wei, Xiao Xu & Qiang Wei. (2023) Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development. Molecular Therapy.
Crossref
Crossref
Amar Yeware, Angelica Helton, Yicheng Dong, Cheng Dong, Justin Pritchard, Shin Mineishi, Kentaro Minagawa, Todd Schell & Daniel Hayes. (2023) Novel fourth generation-like CARmiR cells release therapeutic miRNA via exosomes and enhance glioblastoma cell killing activity. Biochemical Engineering Journal 199, pages 109068.
Crossref
Crossref
Jiuhui Xu, Qianyu Shi, Boyang Wang, Tao Ji, Wei Guo, Tingting Ren & Xiaodong Tang. (2023) The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies. Frontiers in Immunology 14.
Crossref
Crossref
Xiaoling Shen, Rusong ZhangXiaojuan NieYanhua YangYe HuaPeng Lü. (2023) 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T. Cancer Biotherapy and Radiopharmaceuticals 38:7, pages 431-444.
Crossref
Crossref
Vardges Tserunyan & Stacey D. Finley. (2023) A systems and computational biology perspective on advancing CAR therapy. Seminars in Cancer Biology 94, pages 34-49.
Crossref
Crossref
Audrey Page, Marie Delles, Didier Nègre, Caroline Costa, Floriane Fusil & François-Loïc Cosset. (2023) Engineering B cells with customized therapeutic responses using a synthetic circuit. Molecular Therapy - Nucleic Acids 33, pages 1-14.
Crossref
Crossref
A. Neeser, R. Ramasubramanian, C. Wang & L. Ma. (2023) Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors. Immuno-Oncology and Technology 19, pages 100385.
Crossref
Crossref
Yangyang Xie, Xiaotong Li, Jingyi Wu, Huiling Zeng, Hamza Boucetta, Binru Wang, Pei Yang & Wei He. (2023) CAR-T cells for cancer immunotherapy. Chinese Chemical Letters 34:9, pages 108202.
Crossref
Crossref
Samaneh Keshavarz, Jack R. Wall, Somayeh Keshavarz, Elham Vojoudi & Reza Jafari-Shakib. (2023) Breast cancer immunotherapy: a comprehensive review. Clinical and Experimental Medicine.
Crossref
Crossref
Martina Imbimbo, Laureline Wetterwald, Alex Friedlaender, Kaushal Parikh & Alfredo Addeo. (2023) Cellular Therapy in NSCLC: Between Myth and Reality. Current Oncology Reports.
Crossref
Crossref
Malena Bodden, Aline Häcker, Jasmin Röder, Anne Kiefer, Congcong Zhang, Anita Bhatti, Jordi Pfeifer Serrahima, Evelyn Ullrich, Ines Kühnel & Winfried S. Wels. (2023) Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD2-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2. Cancers 15:17, pages 4310.
Crossref
Crossref
Xiangyu Zhao, Minghao Lin & Xiaojun Huang. (2023) Current status and future perspective of natural killer cell therapy for cancer. Medical Review 3:4, pages 305-320.
Crossref
Crossref
Preeti Dabas & Adithi Danda. (2023) Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. Medical Oncology 40:9.
Crossref
Crossref
Antonio Pontoriero, Paola Critelli, Federico Chillari, Giacomo Ferrantelli, Miriam Sciacca, Anna Brogna, Silvana Parisi & Stefano Pergolizzi. (2023) Modulation of Radiation Doses and Chimeric Antigen Receptor T Cells: A Promising New Weapon in Solid Tumors—A Narrative Review. Journal of Personalized Medicine 13:8, pages 1261.
Crossref
Crossref
Yalan Zhang, Weilin Zhou, Jiangping Yang, Jinrong Yang & Wei Wang. (2023) Chimeric antigen receptor engineered natural killer cells for cancer therapy. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Gede Kambayana & Sandra Surya Rini. (2023) Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as
the Future of Systemic Lupus Erythematosus Treatment. Current Rheumatology Reviews 19:3, pages 260-269.
Crossref
Crossref
Dandan Gao, Fei Hong & Aili He. (2023)
The role of bone marrow microenvironment on
CAR‐T
efficacy in haematologic malignancies
. Scandinavian Journal of Immunology 98:2.
Crossref
Crossref
Ri Han Wu, Chen Ying Zhu, Pei Han Yu, Yafang Ma, Liaqat Hussain, Hua Naranmandura & Qian Qian Wang. (2023) The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions. Toxicology and Applied Pharmacology 473, pages 116585.
Crossref
Crossref
Marco Ventin, Giulia Cattaneo, Luke Maggs, Jingyu Jia, Shahrzad Arya, Soldano Ferrone, Xinhui Wang & Cristina R. Ferrone. (2023) B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers. Frontiers in Oncology 13.
Crossref
Crossref
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, Sabah Nisar, Maysaloun Merhi, Sheema Hashem, Ravi Chauhan, Manisha Dagar, Sameer Mirza, Puneet Bagga, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Mohammad Haris, Shahab Uddin, Mayank Singh & Ajaz A. Bhat. (2023) Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. Journal of Translational Medicine 21:1.
Crossref
Crossref
Peizhen Geng, Yuhua Chi, Yuan Yuan, Maoquan Yang, Xiaohua Zhao, Zhengchun Liu, Guangwei Liu, Yihui Liu, Liang Zhu & Shuai Wang. (2023) Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Crossref
Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia & Giuseppe Sconocchia. (2023) Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond. Cancers 15:13, pages 3346.
Crossref
Crossref
Nawar Maher, Samir Mouhssine, Bassam Francis Matti, Alaa Fadhil Alwan & Gianluca Gaidano. (2023) Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers. International Journal of Molecular Sciences 24:12, pages 10374.
Crossref
Crossref
Min Hwa Shin, Eunha Oh, Yunjeong Kim, Dae-Hwan Nam, So Young Jeon, Jin Hyuk Yu & Dohsik Minn. (2023) Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells 12:12, pages 1606.
Crossref
Crossref
Hiu Kwan Carolyn Tang, Bo Wang, Hui Xian Tan, Muhammad Adeel Sarwar, Bahaaeldin Baraka, Tahir Shafiq & Ankit R. Rao. (2023) CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours. Cells 12:12, pages 1586.
Crossref
Crossref
Konstantinos Drougkas, Konstantinos Karampinos, Ioannis Karavolias, Ioannis-Alexios Koumprentziotis, Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis Trontzas & Elias Kotteas. (2022) Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. Journal of Cancer Research and Clinical Oncology 149:6, pages 2709-2734.
Crossref
Crossref
Mingming Wang, Xiaojie Wang, Xiaoyan Jin, Jingjing Zhou, Yufu Zhang, Yiyuan Yang, Yusi Liu & Jing Zhang. (2023) Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions. Frontiers in Immunology 14.
Crossref
Crossref
Ruonan Li & Lili Cao. (2023) The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy. Frontiers in Immunology 14.
Crossref
Crossref
Kaveh Hadiloo, Safa Tahmasebi & Abdolreza Esmaeilzadeh. (2023) CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell International 23:1.
Crossref
Crossref
Marisa K. Kilgour, Donald J. Bastin, Seung-Hwan Lee, Michele Ardolino, Scott McComb & Alissa Visram. (2023) Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Frontiers in Immunology 14.
Crossref
Crossref
Miao Wang, Angus W. Thomson, Fang Yu, Rimi Hazra, Aditi Junagade & Xiaoming Hu. (2022) Regulatory T lymphocytes as a therapy for ischemic stroke. Seminars in Immunopathology 45:3, pages 329-346.
Crossref
Crossref
Tianyu Terry Gao, Teak‐Jung Oh, Kritika Mehta, Yu‐En Andrew Huang, Tyler Camp, Huaxun Fan, Jeong Won Han, Collin Michael Barnes & Kai Zhang. (2023) The clinical potential of optogenetic interrogation of pathogenesis. Clinical and Translational Medicine 13:5.
Crossref
Crossref
Lingfeng Yu, Gong Lanqing, Ziyu Huang, Xiaoyan Xin, Liang Minglin, Lv Fa-hui, Hongmei Zou & Jie Min. (2023) T cell immunotherapy for cervical cancer: challenges and opportunities. Frontiers in Immunology 14.
Crossref
Crossref
Ravi Teja Chitturi Suryaprakash, Mohammad Ayman Abdulkarim Safi, Noufa Alonazi, Ahdab A. Alsieedi & Omar Kujan. 2023. Molecular Targets and Cancer Therapeutics (Part 2). Molecular Targets and Cancer Therapeutics (Part 2)
165
235
.
Samane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, Saba Hajazimian, Pouya Goleij, Javad Behroozi, Behrouz Shademan, Alireza Isazadeh & Behzad Baradaran. (2022)
Chimeric antigen receptor T (
CAR‐T
) cells: Novel cell therapy for hematological malignancies
. Cancer Medicine 12:7, pages 7844-7858.
Crossref
Crossref
Shanglin Yang. (2023) CAR-T cells therapy: a potential new strategy against prostate cancer. Highlights in Science, Engineering and Technology 36, pages 1468-1473.
Crossref
Crossref
Mengfei Chen, Haoze Li & Yinxuan Wu. (2023) Development and Clinical Application of CAR-T Therapy. Highlights in Science, Engineering and Technology 36, pages 1269-1276.
Crossref
Crossref
Nicole Cruz-Reyes & Derek C. Radisky. (2023) Inflammation, Infiltration, and Evasion—Tumor Promotion in the Aging Breast. Cancers 15:6, pages 1836.
Crossref
Crossref
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, Sara Bleve, Chiara Casadei, Cristian Lolli, Laura Ridolfi, Giovanni Martinelli & Ugo De Giorgi. (2023) The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. Cancers 15:5, pages 1597.
Crossref
Crossref
Xinping Cao, Xin Jin, Xiaomei Zhang, Paudel Utsav, Yi Zhang, Ruiting Guo, Wenyi Lu & Mingfeng Zhao. (2023) Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies. Current Treatment Options in Oncology 24:3, pages 184-211.
Crossref
Crossref
Duc Huynh, Pia Winter, Florian Märkl, Stefan Endres & Sebastian Kobold. (2022) Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment. Seminars in Immunopathology 45:2, pages 215-227.
Crossref
Crossref
Zhifen Yang, Violena Pietrobon, Maggie Bobbin, Ofir Stefanson, Jin Yang, Angshumala Goswami, Bennett Alphson, Hana Choi, Khristina Magallanes, Qi Cai, David Barrett, Bing Wang, Lei S. Qi & Francesco M. Marincola. (2023) Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment. Journal of Translational Medicine 21:1.
Crossref
Crossref
Sara Pagotto, Pasquale Simeone, Davide Brocco, Giulia Catitti, Domenico De Bellis, Simone Vespa, Natalia Di Pietro, Lisa Marinelli, Antonio Di Stefano, Serena Veschi, Laura De Lellis, Fabio Verginelli, Francesco Kaitsas, Manuela Iezzi, Assunta Pandolfi, Rosa Visone, Nicola Tinari, Ignazio Caruana, Mauro Di Ianni, Alessandro Cama, Paola Lanuti & Rosalba Florio. (2023) CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy. Cancers 15:4, pages 1052.
Crossref
Crossref
Valentine Wang, Mélanie Gauthier, Véronique Decot, Loïc Reppel & Danièle Bensoussan. (2023) Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input. Cancers 15:4, pages 1003.
Crossref
Crossref
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil & Maryam Abbaspour. (2022) Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Communications 43:2, pages 177-213.
Crossref
Crossref
Christopher J. Fay, Katherine C. Awh, Nicole R. LeBoeuf & Cecilia A. Larocca. (2023) Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Frontiers in Oncology 12.
Crossref
Crossref
Wan-Soo Yoon & Dong-Sup Chung. (2023) Advanced T and NK Cell Therapy for Glioblastoma. Journal of Korean Neurosurgical Society.
Crossref
Crossref
Inês S. Pinto, Rosemeyre A. Cordeiro & Henrique Faneca. (2023) Polymer- and lipid-based gene delivery technology for CAR T cell therapy. Journal of Controlled Release 353, pages 196-215.
Crossref
Crossref
Azadeh Sadat Razavi, Angelica Loskog, Sepideh Razi & Nima Rezaei. (2023) The signaling and the metabolic differences of various CAR T cell designs. International Immunopharmacology 114, pages 109593.
Crossref
Crossref
Nathan El Ghazzi, Antoine Italiano, Jacques-Olivier Bay & Aurore Dougé. (2023) Développement des CAR-T cells dans les tumeurs solides. Bulletin du Cancer 110:1, pages 32-41.
Crossref
Crossref
Hind Rafei, Rafet Basar, Katayoun Rezvani & May Daher. 2023. NK Cells in Cancer Immunotherapy: Successes and Challenges. NK Cells in Cancer Immunotherapy: Successes and Challenges
97
131
.
Abdolreza Esmaeilzadeh, Davood Jafari, Reza Elahi, Mahsa Bazargan, Maryam Zare Rafie & Amir Hossein Mansourabadi. 2023.
Ryo MIZUTA, Yoshihiro OTANI, Kentaro FUJII, Atsuhito UNEDA, Joji ISHIDA, Takehiro TANAKA, Shuntaro IKEGAWA, Nobuharu FUJII, Yoshinobu MAEDA & Isao DATE. (2022) A Case of Relapsed Primary Central Nervous System Lymphoma Treated with CD19-directed Chimeric Antigen Receptor T Cell Therapy. NMC Case Report Journal 9:0, pages 275-280.
Crossref
Crossref
Zhifeng Zhou, Jieyu Li, Jingwen Hong, Shuping Chen, Mingshui Chen, Ling Wang, Wansong Lin & Yunbin Ye. (2022) Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer. Frontiers in Immunology 13.
Crossref
Crossref
Rita Assi & Huda Salman. (2022) Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?. Cells 11:24, pages 3971.
Crossref
Crossref
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, Faeze Salem, Mojtaba Nikbakht, Sahar Evazi Bakhshi & Pooria Safarzadeh Kozani. (2022) Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Research 10:1.
Crossref
Crossref
Ying Shi, Mengwan Wu, Yuyang Liu, Ling Chen, Xiuwu Bian & Chuan Xu. (2022) Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. Journal of Bio-X Research 5:4, pages 151-162.
Crossref
Crossref
Janina Niebling, Wolfgang Bethge & Claudia Lengerke. (2022) CAR-T-Zell-Therapie – personalisierte zelluläre Immuntherapie im Jahr 2022. Onkologie up2date 4:04, pages 309-322.
Crossref
Crossref
Dennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, Marcell Kaljanac, Jordan Hartley, Markus Barden, Hong Pan, Astrid Holzinger, Wolfgang Herr & Hinrich Abken. (2022) CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop. Cells 11:23, pages 3839.
Crossref
Crossref
Luisa Chocarro, Ester Blanco, Leticia Fernández-Rubio, Hugo Arasanz, Ana Bocanegra, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Piñeiro-Hermida, Ruth Vera, Grazyna Kochan & David Escors. (2022) Cutting-Edge CAR Engineering: Beyond T Cells. Biomedicines 10:12, pages 3035.
Crossref
Crossref
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani & Pooria Safarzadeh Kozani. (2022) CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology 13.
Crossref
Crossref
Chiara Cassioli, Laura Patrussi, Salvatore Valitutti & Cosima T. Baldari. (2022) Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). International Journal of Molecular Sciences 23:22, pages 14255.
Crossref
Crossref
Abigail Cheever, Michelle Townsend & Kim O’Neill. (2022) Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors. Cells 11:22, pages 3626.
Crossref
Crossref
Judit Rial Saborido, Simon Völkl, Michael Aigner, Andreas Mackensen & Dimitrios Mougiakakos. (2022) Role of CAR T Cell Metabolism for Therapeutic Efficacy. Cancers 14:21, pages 5442.
Crossref
Crossref
Rocío Castellanos-Rueda, Raphaël B. Di Roberto, Florian Bieberich, Fabrice S. Schlatter, Darya Palianina, Oanh T. P. Nguyen, Edo Kapetanovic, Heinz Läubli, Andreas Hierlemann, Nina Khanna & Sai T. Reddy. (2022) speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. Nature Communications 13:1.
Crossref
Crossref
Janina Niebling, Wolfgang Bethge & Claudia Lengerke. (2022) CAR-T-Zell-Therapie – personalisierte zelluläre Immuntherapie im Jahr 2022. DMW - Deutsche Medizinische Wochenschrift 147:23, pages 1552-1564.
Crossref
Crossref
Qianling Ye, Yun Lin, Ruihao Li, Huaiji Wang & Chunyan Dong. (2022) Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Seminars in Cancer Biology 86, pages 607-623.
Crossref
Crossref
Zhongguo Zhou, Can Tao, Jianting Li, Johnny Cheuk-on Tang, Albert Sun-chi Chan & Yuanyuan Zhou. (2022) Chimeric antigen receptor T cells applied to solid tumors. Frontiers in Immunology 13.
Crossref
Crossref
Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye, Zhixiong Liu & Quan Cheng. (2022) Tumor buster - where will the CAR-T cell therapy ‘missile’ go?. Molecular Cancer 21:1.
Crossref
Crossref
Dennis Christoph Harrer, Charlotte Schenkel, Carola Berking, Wolfgang Herr, Hinrich Abken, Jan Dörrie & Niels Schaft. (2022) Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells. Cancers 14:20, pages 5033.
Crossref
Crossref
Guo-Fen Re, Bei-Bei Tang, Jing Kou, Chen Hong & Yi-Qun Kuang. (2022) Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs. Infectious Diseases & Immunity 2:4, pages 253-262.
Crossref
Crossref
Jake Moscarelli, David Zahavi, Rachael Maynard & Louis M. Weiner. (2022) The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells. Transplantation and Cellular Therapy 28:10, pages 650-656.
Crossref
Crossref
Haigang Ding, Juan Zhang, Feng Zhang, Yan Xu, Yijun Yu, Wenqing Liang & Qingping Li. (2022) The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer. Medical Oncology 39:12.
Crossref
Crossref
Ala Amgheib, Ruisi Fu & Eric O. Aboagye. (2022) Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells. Pharmaceutics 14:10, pages 2040.
Crossref
Crossref
Ali Keshavarz, Ali Salehi, Setareh Khosravi, Yasaman Shariati, Navid Nasrabadi, Mohammad Saeed Kahrizi, Sairan Maghsoodi, Amirhossein Mardi, Ramyar Azizi, Samira Jamali & Farnoush Fotovat. (2022) Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. Stem Cell Research & Therapy 13:1.
Crossref
Crossref
Caio Raony Farina Silveira, Amanda Cristina Corveloni, Sâmia Rigotto Caruso, Nathália Araújo Macêdo, Natália Moscheta Brussolo, Felipe Haddad, Taisa Risque Fernandes, Pamela Viani de Andrade, Maristela Delgado Orellana & Renato Luiz Guerino-Cunha. (2022) Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Frontiers in Immunology 13.
Crossref
Crossref
Julie Lasvergnas, Marie Naigeon, Kader Chouahnia, Laurent Zelek, Nathalie Chaput & Boris Duchemann. (2022) Adoptive cell therapies in thoracic malignancies. Cancer Immunology, Immunotherapy 71:9, pages 2077-2098.
Crossref
Crossref
Lei Chen, Ting Xie, Bing Wei & Da-Lin Di. (2022) Current progress in CAR‑T cell therapy for tumor treatment (Review). Oncology Letters 24:4.
Crossref
Crossref
Van To, Vera J. Evtimov, Graham Jenkin, Aleta Pupovac, Alan O. Trounson & Richard L. Boyd. (2022) CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Frontiers in Immunology 13.
Crossref
Crossref
Yuhan Zhang. (2022) T Recent advances of FDA-approved CAR-T therapies in multiple myeloma. Highlights in Science, Engineering and Technology 8, pages 380-389.
Crossref
Crossref
Chentao Li, Ziming Liu & Yue Zhou. (2022) CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements. Highlights in Science, Engineering and Technology 8, pages 54-63.
Crossref
Crossref
Felix Korell, Trisha R. Berger & Marcela V. Maus. (2022) Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med 3:8, pages 538-564.
Crossref
Crossref
Mushtaq Ahmad Nengroo, Ayushi Verma & Dipak Datta. (2022) Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine 156, pages 155916.
Crossref
Crossref
Christopher Zaab-Yen Abana, Helena Lamptey, Evelyn Y. Bonney & George B. Kyei. (2022) HIV cure strategies: which ones are appropriate for Africa?. Cellular and Molecular Life Sciences 79:8.
Crossref
Crossref
Long Chen, Fukun Chen, Huatao Niu, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Rong Huang, Ke Li, Yujie Lei & Yunchao Huang. (2022) Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. Frontiers in Immunology 13.
Crossref
Crossref
Xavier Ramos‑Cardona, Weichuan Luo & Sulma Mohammed. (2022) Advances and challenges of CAR T therapy and suitability of animal models (Review). Molecular and Clinical Oncology 17:3.
Crossref
Crossref
Salomon Manier, Tiziano Ingegnere, Guillaume Escure, Chloé Prodhomme, Morgane Nudel, Suman Mitra & Thierry Facon. (2022) Current state and next-generation CAR-T cells in multiple myeloma. Blood Reviews 54, pages 100929.
Crossref
Crossref
Shengwen Shang, Yongjie Zhao, Kaiqiang Qian, Yuexuan Qin, Xinyi Zhang, Tianyue Li, Lidong Shan, Meili Wei, Jun Xi & Bikui Tang. (2022) The role of neoantigens in tumor immunotherapy. Biomedicine & Pharmacotherapy 151, pages 113118.
Crossref
Crossref
Maysam Mansouri & Martin Fussenegger. (2021) Therapeutic cell engineering: designing programmable synthetic genetic circuits in mammalian cells. Protein & Cell 13:7, pages 476-489.
Crossref
Crossref
Christoforos K. Vaxevanis, Michael Friedrich, Sandy Uta Tretbar, Diana Handke, Yuan Wang, Juliane Blümke, Reinhard Dummer, Chiara Massa & Barbara Seliger. (2022) Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma. Clinical and Translational Medicine 12:7.
Crossref
Crossref
Harish Sudarsanam, Raymund Buhmann & Reinhard Henschler. (2022) Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Shang Mengxuan, Zhou Fen & Jin Runming. (2022) Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era. Frontiers in Pediatrics 10.
Crossref
Crossref
Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Saqer S. Alotaibi, Mohammad M. Al-Sanea & Hisham Althobaiti. (2022) Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Crossref
Dimitrios L. Wagner, Ulrike Koehl, Markus Chmielewski, Christoph Scheid & Renata Stripecke. (2022) Review: Sustainable Clinical Development of CAR-T Cells – Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. Frontiers in Immunology 13.
Crossref
Crossref
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Eleni Karapedi, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Kostas A. Papavassiliou, Michalis V. Karamouzis & Athanasios G. Papavassiliou. (2022) Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. International Journal of Molecular Sciences 23:12, pages 6664.
Crossref
Crossref
Prameela Kandra, Rajender Nandigama, Bastian Eul, Magdalena Huber, Sebastian Kobold, Werner Seeger, Friedrich Grimminger & Rajkumar Savai. (2022) Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer. Frontiers in Immunology 13.
Crossref
Crossref
Junfeng Chu, Fengcai Gao, Meimei Yan, Shuang Zhao, Zheng Yan, Bian Shi & Yanyan Liu. (2022) Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine 20:1.
Crossref
Crossref
Zeljko Todorovic, Dusan Todorovic, Vladimir Markovic, Nevena Ladjevac, Natasa Zdravkovic, Predrag Djurdjevic, Nebojsa Arsenijevic, Marija Milovanovic, Aleksandar Arsenijevic & Jelena Milovanovic. (2022) CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. Current Oncology 29:5, pages 3647-3657.
Crossref
Crossref
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Milad Ahmadi Najafabadi, Fatemeh Yousefi, Seyed Mohamad Javad Mirarefin & Fatemeh Rahbarizadeh. (2022) Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. Frontiers in Immunology 13.
Crossref
Crossref
Laura Antonucci, Gabriele Canciani, Angela Mastronuzzi, Andrea Carai, Giada Del Baldo & Francesca Del Bufalo. (2022) CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies. Frontiers in Immunology 13.
Crossref
Crossref
Jaquelyn T. Zoine, Chengyu Prince, Jamie Y. Story, Gianna M. Branella, Allison M. Lytle, Andrew Fedanov, Jordan S. Alexander, Christopher C. Porter, Christopher B. Doering, H. Trent Spencer & Shanmuganathan Chandrakasan. (2021) Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells. Gene Therapy 29:5, pages 1-12.
Crossref
Crossref
Gideon Gross, Yaron Carmi & Hinrich Abken. (2022) Editorial: Implementing Logic Gates in Adoptive Cell Therapy. Frontiers in Immunology 13.
Crossref
Crossref
Gina López-Cantillo, Claudia Urueña, Bernardo Armando Camacho & Cesar Ramírez-Segura. (2022) CAR-T Cell Performance: How to Improve Their Persistence?. Frontiers in Immunology 13.
Crossref
Crossref
Tingxi Guo, Dacheng Ma & Timothy K. Lu. (2022) Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation. ACS Synthetic Biology 11:4, pages 1440-1453.
Crossref
Crossref
Luisa Chocarro, Hugo Arasanz, Leticia Fernández-Rubio, Ester Blanco, Miriam Echaide, Ana Bocanegra, Lucía Teijeira, Maider Garnica, Idoia Morilla, Maite Martínez-Aguillo, Sergio Piñeiro-Hermida, Pablo Ramos, Juan José Lasarte, Ruth Vera, Grazyna Kochan & David Escors. (2022) CAR-T Cells for the Treatment of Lung Cancer. Life 12:4, pages 561.
Crossref
Crossref
Rebecca C Abbott, Hannah E Hughes-Parry & Misty R Jenkins. (2022) To go or not to go? Biological logic gating engineered T cells. Journal for ImmunoTherapy of Cancer 10:4, pages e004185.
Crossref
Crossref
Long Chen, Fukun Chen, Jindan Li, Yongzhu Pu, Conghui Yang, Yue Wang, Yujie Lei & Yunchao Huang. (2022)
CAR‐T
cell therapy for lung cancer: Potential and perspective
. Thoracic Cancer 13:7, pages 889-899.
Crossref
Crossref
Eva Catalá, Gloria Iacoboni & Pere Barba. (2022) Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivo. Perspectiva actual tras una década de tratamiento. Medicina Clínica 158:7, pages 327-332.
Crossref
Crossref
Eva Catalá, Gloria Iacoboni & Pere Barba. (2022) Chimeric antigen receptor T-cell (CAR-T) therapy in patients with aggressive B-cell lymphomas. Current outlook after a decade of treatment. Medicina Clínica (English Edition) 158:7, pages 327-332.
Crossref
Crossref
Harinad B. Maganti, Aidan M. Kirkham, Adrian J.M. Bailey, Risa Shorr, Natasha Kekre, Nicolas Pineault & David S. Allan. (2022) Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. Cytotherapy 24:4, pages 405-412.
Crossref
Crossref
Ler Yie Chan, Sylvia Annabel Dass, Gee Jun Tye, Siti A. M. Imran, Wan Safwani Wan Kamarul Zaman & Fazlina Nordin. (2022) CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review. Biomedicines 10:4, pages 804.
Crossref
Crossref
Siyuan Qian, Pedro Villarejo-Campos, Ismael Guijo, Sergio Hernández-Villafranca, Damián García-Olmo, Sara González-Soares, Héctor Guadalajara, Santos Jiménez-Galanes & Cheng Qian. (2022) Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects. Frontiers in Immunology 13.
Crossref
Crossref
Katharina Eva Ruppel, Stephan Fricke, Ulrike Köhl & Dominik Schmiedel. (2022) Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy. Frontiers in Immunology 13.
Crossref
Crossref
Prajna Guha, Kara R. Heatherton, Kyle P. O’Connell, Ian S. Alexander & Steven C. Katz. (2022) Assessing the Future of Solid Tumor Immunotherapy. Biomedicines 10:3, pages 655.
Crossref
Crossref
Anh Nguyen, Gary Johanning & Yihui Shi. (2022) Emerging Novel Combined CAR-T Cell Therapies. Cancers 14:6, pages 1403.
Crossref
Crossref
Anupam DHASMANA, Swati DHASMANA, Sudhir KOTNALA, A ANUKRITI, Vivek K. KASHYAP, Poornima D. SHAJI, Partha LASKAR, Sheema KHAN, Rinaldo PELLICANO, Sharmila FAGOONEE, Shafiul HAQUE, Murali M. YALLAPU, Subhash C. CHAUHAN & Meena JAGGI. (2022) A topography of immunotherapies against gastrointestinal malignancies. Panminerva Medica 64:1.
Crossref
Crossref
Dannel Yeo, Caroline Giardina, Payal Saxena & John E.J. Rasko. (2022) The next wave of cellular immunotherapies in pancreatic cancer. Molecular Therapy - Oncolytics 24, pages 561-576.
Crossref
Crossref
Yao Jiang, Weihong Wen, Fa Yang, Donghui Han, Wuhe Zhang & Weijun Qin. (2022) Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. Cancers 14:4, pages 967.
Crossref
Crossref
Shirin Teymouri Nobari, Jafar Nouri Nojadeh & Mehdi Talebi. (2022) B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages. Journal of Translational Medicine 20:1.
Crossref
Crossref
Xiao-Hong Chen, Ruo Chen, Ming-Yan Shi, Ruo-Fei Tian, Hai Zhang, Zhi-Qian Xin, Zhi-Nan Chen & Ke Wang. (2022) Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. Translational Oncology 16, pages 101309.
Crossref
Crossref
Ali Zarezadeh Mehrabadi, Reza Ranjbar, Mahdieh Farzanehpour, Alireza Shahriary, Ruhollah Dorostkar, Mohammad Ali Hamidinejad & Hadi Esmaeili Gouvarchin Ghaleh. (2022) Therapeutic potential of CAR T cell in malignancies: A scoping review. Biomedicine & Pharmacotherapy 146, pages 112512.
Crossref
Crossref
Franziska Füchsl & Angela M. Krackhardt. (2022) Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. Cells 11:3, pages 410.
Crossref
Crossref
Mahasha P.J. Perera, Patrick B. Thomas, Gail P. Risbridger, Renea Taylor, Arun Azad, Michael S. Hofman, Elizabeth D. Williams & Ian Vela. (2022) Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. Cancers 14:3, pages 503.
Crossref
Crossref
Astrid Holzinger & Hinrich Abken. (2022) Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells. Pharmacology 107:9-10, pages 446-463.
Crossref
Crossref
Qingmin Mei, Wei Wang, Jianjun Wu & Yong Gao. (2022) Advances in HIV Eradication Strategies. Infectious Microbes and Diseases 4:2, pages 64-70.
Crossref
Crossref
Rui Mao, Mohamed S. Hussein & Yukai He. (2022) Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours. Expert Reviews in Molecular Medicine 24.
Crossref
Crossref
Wanying Zeng & Pumin Zhang. (2022) Resistance and recurrence of malignancies after CAR-T cell therapy. Experimental Cell Research 410:2, pages 112971.
Crossref
Crossref
Dominic A. Boardman & Megan K. Levings. (2022) Emerging strategies for treating autoimmune disorders with genetically modified Treg cells. Journal of Allergy and Clinical Immunology 149:1, pages 1-11.
Crossref
Crossref
Seyedeh Ameneh Beheshti, Karim Shamsasenjan, Majid Ahmadi & Batol Abbasi. (2022) CAR Treg: A new approach in the treatment of autoimmune diseases. International Immunopharmacology 102, pages 108409.
Crossref
Crossref
Prajna Guha & Steven C. Katz. 2022. CAR T cells: development, characterization and applications. CAR T cells: development, characterization and applications
203
226
.
Renpeng Ding, Cheng-Chi Chao & Qianqian Gao. 2022. CAR T cells: development, characterization and applications. CAR T cells: development, characterization and applications
1
14
.
José Yélamos. 2022. New Antibody Formats. New Antibody Formats
1
43
.
Ondřej Vaněk, Barbora Kalousková, Celeste Abreu, Shiva Nejadebrahim & Ondřej Skořepa. 2022. Immunotherapeutics. Immunotherapeutics
91
133
.
Jules J. Berman. 2022. Classification Made Relevant. Classification Made Relevant
251
341
.
David C. Soler, Amber Kerstetter-Fogle, Thomas S. McCormick & Andrew E. Sloan. (2021) Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments. Journal of Neuro-Oncology 156:1, pages 81-96.
Crossref
Crossref
Goutam Chowdhury & Dharanidharan Ramamurthy. 2022. Human Microbiome. Human Microbiome
73
107
.
Marcus Rafael Lobo Bezerra, Larissa Queiroz Pontes, Igor Cabral Studart, Bruna de Sousa Lima & Gilvan Pessoa Furtado. 2022. The Golden Guide to Oncologic Pharmacy. The Golden Guide to Oncologic Pharmacy
281
314
.
Handi Cao & Ryohichi Sugimura. 2022. Cancer Immunotherapies. Cancer Immunotherapies
255
274
.
Diana C. DeLucia & John K. Lee. 2022. Cancer Immunotherapies. Cancer Immunotherapies
1
48
.
Christian Chabannon & Chiara Bonini. 2022. The EBMT/EHA CAR-T Cell Handbook. The EBMT/EHA CAR-T Cell Handbook
3
5
.
Safa Tahmasebi, Elnaz Khosh, Samaneh Rostami & Nima Rezaei. 2022.
Muhammad Babar Khawar & Haibo Sun. (2021) CAR-NK Cells: From Natural Basis to Design for Kill. Frontiers in Immunology 12.
Crossref
Crossref
Bruktawit Maru, Lea Nadeau & Maureen McKeague. (2021) Enhancing CAR-T Cell Therapy with Functional Nucleic Acids. ACS Pharmacology & Translational Science 4:6, pages 1716-1727.
Crossref
Crossref
Zixun Yin, Ya Zhang & Xin Wang. (2021) Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Biomarker Research 9:1.
Crossref
Crossref
Andres Cubillos-Ruiz, Tingxi Guo, Anna Sokolovska, Paul F. Miller, James J. Collins, Timothy K. Lu & Jose M. Lora. (2021) Engineering living therapeutics with synthetic biology. Nature Reviews Drug Discovery 20:12, pages 941-960.
Crossref
Crossref
Ayda Baghery Saghchy Khorasani, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Seyed H. Ghaffari & Davood Bashash. (2021) CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges. International Immunopharmacology 101, pages 108260.
Crossref
Crossref
Hyeon Joo Yoo & Biyan Nathanael Harapan. (2021) Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology. Immunologic Research 69:6, pages 471-486.
Crossref
Crossref
Mohammed Azharuddin Savanur, Hadas Weinstein-Marom & Gideon Gross. (2021) Implementing Logic Gates for Safer Immunotherapy of Cancer. Frontiers in Immunology 12.
Crossref
Crossref
Weizhen Li, Yang Zhou, Zhongen Wu, Yaoping Shi, Enming Tian, Yingqi Zhu, Tao Wang, Wei Dou, Xiangjing Meng, Ming Chen, Bo Zhai & Di Zhu. (2021) Targeting Wnt Signaling in the Tumor Immune Microenvironment to Enhancing EpCAM CAR T-Cell therapy. Frontiers in Pharmacology 12.
Crossref
Crossref
Bu-Fan Xiao, Jing-Tao Zhang, Yu-Ge Zhu, Xin-Run Cui, Zhe-Ming Lu, Ben-Tong Yu & Nan Wu. (2021) Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges. Frontiers in Immunology 12.
Crossref
Crossref
Laeth L. George, Saarang R. Deshpande, Matthew J. Cortese, Ellen K. Kendall, Asmi Chattaraj, Zunairah Shah, Jianjun Zhao & Faiz Anwer. (2021) Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clinical Lymphoma Myeloma and Leukemia 21:11, pages 741-751.
Crossref
Crossref
Cristina Aparicio, Marina Belver, Lucía Enríquez, Francisco Espeso, Lucía Núñez, Ana Sánchez, Miguel Ángel de la Fuente & Margarita González-Vallinas. (2021) Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. International Journal of Molecular Sciences 22:21, pages 11781.
Crossref
Crossref
Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Pérez-Martínez, Manel Juan & Cristina Eguizabal. (2021) The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers. Cancers 13:21, pages 5418.
Crossref
Crossref
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani & Fatemeh Rahbarizadeh. (2021) Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward. Frontiers in Immunology 12.
Crossref
Crossref
Lauren R. Schaff & Christian Grommes. (2021) Update on Novel Therapeutics for Primary CNS Lymphoma. Cancers 13:21, pages 5372.
Crossref
Crossref
Zachary D. Crees & Armin Ghobadi. (2021) Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. Cancers 13:20, pages 5181.
Crossref
Crossref
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou & Li Zhu. (2021) Advances in Universal CAR-T Cell Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Hinrich Abken. (2021) Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors. Human Gene Therapy 32:19-20, pages 1011-1028.
Crossref
Crossref
Audrey Page, Julie Hubert, Floriane Fusil & François-Loïc Cosset. (2021) Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors. International Journal of Molecular Sciences 22:18, pages 9991.
Crossref
Crossref
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani & Fatemeh Rahbarizadeh. (2021) Chimeric Antigen Receptor T-Cell Therapy: An Overview of the Changing Face of Cancer Immunotherapy. Trends in Medical Sciences 2:1.
Crossref
Crossref
Philipp Wolf, Jamal Alzubi, Christian Gratzke & Toni Cathomen. (2021) The potential of CAR T cell therapy for prostate cancer. Nature Reviews Urology 18:9, pages 556-571.
Crossref
Crossref
Displaying 200 of 407 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list